Schrödinger, Inc.

NasdaqGS SDGR

Schrödinger, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 65.67 M

Schrödinger, Inc. Net Cash Used For Investing Activities is USD 65.67 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -75.14% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Schrödinger, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 264.20 M, a 368.66% change year over year.
Schrödinger, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 56.38 M, a 217.55% change year over year.
Schrödinger, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -47.96 M, a 85.11% change year over year.
Schrödinger, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -322.11 M, a -439.98% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: SDGR

Schrödinger, Inc.

CEO	Dr. Ramy Farid Ph.D.
IPO Date	Feb. 6, 2020
Location	United States
Headquarters	1540 Broadway
Employees	900
Sector	Healthcare
Industries Biotechnology 3D Printing Big Data Chemicals & Advanced Materials Clinical Trials Hardware & Electronics Pharmaceuticals Robotics

Description

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Key trends

Past 5 years